Japanese pharmaceutical company Astellas Pharma is set to acquire Belgian drug discovery company Ogeda with an identical definitive agreement also signed.

"Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%."

The consideration for the acquisition is €500m ($532.5m) in an initial cash payment to acquire 100% equity in the target company at the closing of the agreement, and an additional €300m ($319.49m) upon attaining clinical development and regulatory milestones for a drug named fezolinetant.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition is expected to be completed in the second quarter of this year.

Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%.

GLG Pharma is a biotechnology company based in the US.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.